 registered, between 2017 and 2020, an increase of 8% in turnover and 15% in profits.){kind=link}
Romanian drug producer Biofarm (BIO) registered, between 2017 and 2020, an increase of 8% in turnover and 15% in profits.
The company recorded an 15% increase in EBITDA between 2017-2020, and its’s liquidity increased from 37 million lei in 2017, to 121 million lei in the first semester of 2021.
Net sales revenues achieved in the first semester of 2021 were over 117 million lei on the rise by 14% as compared to the first semester of 2020.
Biofarm exports its products to countries such as Azerbaijan, Russia, Georgia, Kurdistan/Iraq, Kyrgyzstan, Malta, the Republic of Moldova, Hungary, and Ukraine.
The company is in the process of negotiating with several states in the region of Southeast Europe, Central and Southeast Asia, Africa, and the Arab region.